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Abstract: Growing evidence suggests that pharmacotherapy may be beneficial for some patients 
with binge eating disorder (BED), an eating disorder characterized by repetitive episodes of 
uncontrollable consumption of abnormally large amounts of food without inappropriate weight 
loss behaviors. In this paper, we provide a brief overview of BED and review the rationales and 
data supporting the effectiveness of specific medications or medication classes in treating patients 
with BED. We conclude by summarizing these data, discussing the role of pharmacotherapy in 
the BED treatment armamentarium, and suggesting future areas for research.
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Introduction
Binge eating disorder (BED) is an eating disorder characterized by recurrent, distressing 
binge-eating episodes without the inappropriate compensatory weight loss behaviors 
of bulimia nervosa.1,2 Increasing research indicates BED is an important public health 
problem. It is common, with an estimated lifetime prevalence in the US and Western 
Europe of 1%–3%.3,4 In addition, BED is increasing in prevalence, is often chronic, 
and is associated with psychiatric comorbidity, obesity and other medical conditions, 
and disability.3,5–9
The therapeutic armamentarium for BED is growing, but treatment remains a 
challenge (Table 1).10,11 Specialized psychotherapies, in particular cognitive behavior 
therapy (CBT) and interpersonal therapy, and self-help strategies are effective for 
reducing binge eating, but not all patients respond adequately.10,12 Moreover, these 
treatments are generally not effective for the obesity associated with BED, and patients 
with more complex yet common comorbid comorbidities, such as bipolar disorder, 
severe personality disorders, or unstable diabetes or hypertension, have been excluded 
from study participation, raising questions about the generalizability of treatment 
effectiveness. On the other hand, bariatric surgery may reduce binge eating and induce 
clinically significant weight loss in obese patients with BED.13 However, the litera-
ture is inconsistent as to how binge eating affects response to bariatric surgery, with 
some studies indicating that binge eating is associated with less weight loss and more 
subsequent weight regain.14–16 Moreover, a sizeable proportion of surgical patients 
have binge eating episodes approximately 2 years after surgery.17 Therefore, novel 
treatments are needed for BED.
A number of reviews18–24 and guidelines25–27 have recently discussed the role phar-
macotherapy might play in treating patients with BED. However, no drug has been 
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Table 1 Nonpharmacological treatments for BED
Modalitya Qualitative findings
Psychotherapy
Cognitive behavioral therapy Decreases binge eating behavior, associated eating disorder psychopathology, and depressive symptoms.  
Does not result in clinically meaningful weight loss. Antibinging benefits maintained on follow-up.
Interpersonal therapy Decreases binge eating behavior, associated eating disorder psychopathology, and depressive symptoms.  
Does not result in clinically meaningful weight loss. Antibinging benefits maintained on follow-up.
Dialectical behavior therapy Decreases binge eating behavior and associated eating disorder psychopathology without producing clinically 
meaningful weight loss.
Behavioral weight loss May reduce binge eating behavior and associated eating pathology in some patients. Often produces short-term 
weight loss. Might be suitable for BED patients without high levels of specific eating disorder psychopathology.
Self-helpb Decreases binge eating behavior and eating disorder psychopathology but does not result in clinically 
meaningful weight loss.
Combination treatmentsc Decreases binge eating behavior and associated eating disorder psychopathology without producing clinically 
meaningful weight loss.
Bariatric surgery Decreases binge eating behavior and eating disorder psychopathology along with producing clinically significant 
weight loss. Preoperative BED and postoperative loss of control eating may be associated with less weight loss 
or more weight gain, but findings are mixed.
Notes: aRandomized controlled trials were preferentially evaluated for this summary, when available; bincludes CBT self-help, guided CBT self-help, CBT partial self-help, and 
telephone-based guided self-help; cincludes studies of CBT plus weight loss treatment; CBT plus nutritional counseling; and CBT plus physical activity. 
Abbreviations: BED, binge-eating disorder; CBT, cognitive behavioral therapy.
approved by the US Food and Drug Administration or any 
other regulatory agency for the treatment of this   condition. 
Moreover, there has been little discussion as to where 
pharmacotherapy fits into the therapeutic armamentarium 
for BED.
In this review, we first provide a brief overview of BED 
and the rationales for using medication in the treatment 
of this condition. We then review the data supporting the 
effectiveness of specific medications or medication classes 
in treating patients with BED. We conclude by summarizing 
these data and discussing the role pharmacotherapy might 
play in the treatment of BED. We also suggest future areas 
for research in BED pharmacotherapy.
Overview of binge eating disorder
BED is the most common eating disorder in the US, with 
a lifetime prevalence of 2.5% in adults3 and 1.6% in ado-
lescents.28 It has both similarities to and differences from 
bulimia nervosa.2,29 Like bulimia nervosa, a core feature is 
recurrent, distressing binge eating episodes. Binge eating 
episodes are defined in the Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition (DSM-IV) as: eating in a 
discrete period of time an amount of food that is definitely 
larger than most people would eat in a similar period under 
similar circumstances and with a sense of lack of control 
over eating during the episode.1 The regular occurrence 
of inappropriate compensatory behaviors characteristic 
of bulimia nervosa do not occur in BED, though some 
patients engage in such behaviors infrequently. Like bulimia 
  nervosa, BED is more common in females, associated with 
shape and weight concerns in addition to binge eating, may 
be chronic, and is associated with elevated rates of mood, 
anxiety, and substance use disorders.2 However, in bulimia 
nervosa, whereas dieting often precedes binge eating, binge 
eating may antedate sporadic attempts to control weight in 
BED.29,30 Laboratory studies indicate binge eating episodes 
may be smaller in BED than in bulimia nervosa,31 while 
preliminary psychological and neuroimaging findings sug-
gest that BED is disproportionally associated with increased 
reward sensitivity and stronger medial orbitofrontal cortex 
responsivity while viewing food compared with patients 
suffering from bulimia nervosa and healthy controls.32 Also, 
in contrast with bulimia nervosa, BED is more common in 
males, has a later age of onset in adult cohorts, and is more 
often associated with obesity.3 For example, in the National 
Comorbidity Survey Replication, the mean ± standard devia-
tion age of onset for BED was 25.4 ± 1.2 years as compared 
with 19.7 ± 1.3 years for bulimia nervosa.3 In addition, 
42% of individuals with BED were obese (as defined by a 
body mass index [BMI] $ 30 mg/kg2), with 15% having a 
BMI $ 40 mg/kg2, as compared with 31% and 10%, respec-
tively, for individuals with bulimia nervosa.3
BED overlap with obesity is so extensive that some 
have questioned whether they are truly distinct entities.29 
However, not all individuals with BED are overweight or 
obese.33 In addition, compared with obese individuals without 
BED, obese individuals with BED have greater concerns 
about shape and body weight and greater body dissatisfac-
tion, report lower quality of life, consume more calories in 
laboratory-based studies, have greater cognitive deficits on 
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neuropsychological testing, have higher rates of comorbid 
Axis I and Axis II disorders, have higher rates of mood dis-
orders and obesity in first-degree relatives, and may have a 
distinct neurobiology.2,6,34–37
These converging lines of evidence have led to the con-
sensus that BED is a valid eating disorder subtype distinct 
from bulimia nervosa and obesity, and to the recommendation 
that it be elevated from inclusion in the DSM-IV appendix 
to a formal disorder in DSM-5.2,38,39 Research showing BED 
individuals who binge eat once per week are comparable 
with those who binge at least twice per week has led to the 
proposal that recurrent binge eating need occur at least once 
a week for 3 months, similar to that in bulimia nervosa, to 
meet the new proposed DSM-5 criteria for BED.40 It has been 
suggested this modification should not substantially change 
prevalence estimates of BED.41
Rationale for using pharmacotherapy 
in treating binge eating disorder
There are several rationales for using pharmacotherapy to 
treat BED. First, mounting evidence indicates that BED, like 
other eating disorders and the mood, anxiety, and substance 
use disorders it co-occurs with, is a mental disorder with 
genetic contributions and neurobiological abnormalities that 
causes distress and disability and does not always respond 
adequately to available psychological interventions.42 Some 
patients, including those with chronic or intractable illness, 
need medication for optimal outcomes.43
Second, as more is learned about the biology of eating 
behavior, disordered eating, and obesity,44 preclinical and 
neuroimaging work is beginning to elucidate a neurobiology 
of binge eating, especially for bulimia nervosa, but also for 
BED.45,46 Animal models of binge eating suggest potential 
involvement of opioid, dopamine, and norepinephrine 
systems, all of which influence feeding behavior. A recent 
positron emission tomographic study found dopamine 
dysfunction in the caudate of obese humans with BED as 
compared with obese humans without BED.37 Behavioral 
genetics research has suggested that the serotonin system 
may play a critical role, because mice lacking functional 
5HT2C receptors display marked hyperphagia, leading to 
the development of obesity.47 Preclinical work showing 
that alterations to the gastrointestinal tract can affect eat-
ing behavior also has implications for BED. Thus, BED is 
associated with gastric distension,48 and repeated gastric 
distension alters food intake and neuroendocrine profiles 
in rats.49 Additionally, BED might be associated with other 
abnormalities external to the central nervous system, such 
as in adipose tissue-derived hormones.34 Understanding the 
neurobiology of BED will promote development of targeted 
pharmacotherapies.
A third reason is that many available medications 
have effects on appetite and weight that may translate 
into therapeutic effects in BED. Thus, antiobesity agents 
(eg, phentermine and orlistat), stimulants, some antidepres-
sants (bupropion), some antiepileptic drugs (eg, topiramate 
and zonisamide), and some drugs for type 2 diabetes 
(eg, exenatide, liraglutide) are associated with decreased 
appetite and/or weight loss.50–52 Examples of neurotransmitter 
systems involved in the regulation of feeding behavior and 
weight control affected by these drugs include the biogenic 
amines serotonin, norepinephrine, and dopamine (eg, by 
antidepressants, stimulants, and   zonisamide) and the major 
excitatory transmitter glutamate (eg, by topiramate).53–55 
Affected peptides involved in controlling feeding and body 
weight include neuropeptide Y (eg, by topiramate and 
zonisamide),56–58 amylin (by pramlintide), and glucagon-like 
peptide-1 (by exenatide and liraglutide).44,52,59,60 Growing 
research suggests medications with anorectic or weight loss 
effects may be helpful for patients with BED.61,62 Moreover, 
novel pharmaceutical compounds for mood and other mental 
disorders, obesity and diabetes, and epilepsy will likely con-
tinue to come to market.63–68 Some of these agents may prove 
to have beneficial effects on appetite or weight regulation, and 
ultimately therapeutic effects in patients with BED.
Literature search
PubMed was searched up to February 2012 using the fol-
lowing terms: “binge eating”, “binge eating disorder”, “eat-
ing disorder not otherwise specified”, “nonpurging bulimia 
nervosa”, “pharmacotherapy”, “antidepressants”, “antiepi-
leptics”, “antiobesity”, “antipsychotics”, “mood stabilizers”, 
“opioid antagonists”, and “stimulants”. We also used the 
terms of the following individual   medications: “acamprosate”, 
“amphetamine”, “  atomoxetine”, “exenatide”, “  fenfluramine”, 
“  lamotrigine”,  “  liraglutide”,  “  methylphenidate”, 
“  naltrexone”, “pramlintide”, “sibutramine”, “topiramate”, 
and   “zonisamide”. Our search was supplemented by review 
of reference lists of relevant articles.
Pharmacotherapy
We located 22 prospective, randomized, placebo-  controlled 
pharmacotherapy studies of BED or closely related   syndromes 
(Tables 2–4). Most trials were short-term (6–16 weeks) and 
all were conducted in adults who were actively binge   eating. 
The majority of studies excluded patients with serious or 
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.
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c
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c
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.
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.
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.
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.
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.
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w
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c
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u
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r
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w
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w
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w
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.
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w
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w
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c
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w
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.
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c
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e
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i
n
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d
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r
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r
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n
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i
n
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r
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T
P
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I
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o
u
p
 
h
a
d
 
a
 
m
e
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n
 
w
e
i
g
h
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l
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k
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k
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P
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L
e
v
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r
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p
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c
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.
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b
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.
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.
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.
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c
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unstable comorbid psychiatric or medical disorders such 
as bipolar disorder, substance use disorders, diabetes, and 
hypertension or other forms of cardiovascular disease. Many 
studies were monotherapy trials where medication alone was 
compared with placebo alone. Fewer studies were combina-
tion or adjunctive therapy trials in which medication plus a 
psychological intervention was compared with placebo plus 
the psychological intervention.
The primary outcome was usually a measure of the 
frequency of binge eating episodes (binge frequency) or 
binge days (binge day frequency), or the rate of remission 
or response of binge eating behavior. Less frequently, the 
primary outcome was weight loss. Secondary outcome mea-
sures have included general eating disorder psychopathology; 
global clinical improvement; mood, anxiety, obsessive-
compulsive, and impulsive symptoms; body weight, BMI, 
and other metabolic parameters; and adherence with study 
medication.
The medications studied thus far in BED in randomized, 
placebo-controlled studies have been conducted primarily 
with three drug classes, ie, antidepressants, antiobesity 
agents, and antiepileptic drugs.25,42,69 Drug classes that have 
received less study include antiaddiction (or anticraving) 
agents and drugs used for attention deficit hyperactivity 
disorder. The individual studies are reviewed in the follow-
ing text according to drug class, along with the rationales 
prompting their study in BED.
Antidepressants
Several rationales led to studies of antidepressants in BED. 
First is that BED is characterized by binge eating similar to 
that of bulimia nervosa, and antidepressants are efficacious 
in bulimia nervosa.18,70 Tricyclics, monoamine oxidase inhibi-
tors, selective serotonin reuptake inhibitors (SSRIs), and sev-
eral atypical agents (mianserine, trazodone, and bupropion)71 
have all been shown to be superior to placebo for reducing 
the frequency of both binge eating and purging episodes in 
bulimia nervosa.23,70,72 Indeed, the antidepressant fluoxetine is 
the only medication approved by the Food and Drug Admin-
istration for the treatment of an eating disorder, that being 
bulimia nervosa. Second is that BED co-occurs with other 
disorders that are responsive to antidepressants, including 
major depressive disorder, panic disorder, generalized anxiety 
disorder, and obsessive-compulsive disorder.3 Third is that 
BED may be associated with abnormalities in serotonin, 
norepinephrine, and dopamine which are targeted by most 
antidepressant classes.37,73,74 To date, at least 12 prospective, 
randomized, placebo-controlled studies of antidepressants 
have been published in patients with BED as defined by all 
or most of the DSM-IV criteria.75–86 Nine studies evaluated 
antidepressant monotherapy while three compared antide-
pressants in combination with weight loss therapy,81 CBT,87 
or both.86 Eight trials evaluated SSRIs, three evaluated 
tricyclics, and one evaluated a serotonin-norepinephrine 
reuptake inhibitor. The latter assessed duloxetine in BED 
patients with co-occurring depressive disorders.79 All studies 
were small, consisting of 20–85 patients, of short duration, 
ranging from 6 to 20 weeks, and many were associated with 
substantial dropout rates. Some were also associated with 
high placebo response rates.75 Tricyclic doses were low as 
compared with those used in depression; SSRI doses were 
higher, comparable with those recommended for bulimia 
nervosa (ie, 60 mg daily of fluoxetine). A study of fluoxetine 
used doses up to 80 mg/day76 and a study of escitalopram 
used supratherapeutic doses (up to 30 mg/day).78
When viewed collectively, SSRIs led to greater rates 
of reduction in target binge eating, psychiatric, and weight 
symptoms than placebo.21,88 However, most weight reduc-
tions would not be considered clinically significant. Tricyclic 
antidepressants were inconsistent regarding reductions in 
binge eating and weight loss. Duloxetine led to decreased 
binge eating, weight loss, and global improvement in eating 
disorder and depressive symptoms.79
A meta-analysis of seven of these studies (one with a 
tricyclic antidepressant, six with SSRIs) showed significantly 
higher binge eating remission rates for the antidepressant 
group compared with the placebo group: 40.5% versus 22.2% 
(relative risk [RR] 0.77; 95% CI 0.65–0.92; P = 0.003).89 
Evaluating studies that used the Hamilton Depression 
  Rating Scale to evaluate change in depressive symptoms, 
a statistically significant difference between groups was 
also seen favoring antidepressants (standardized mean 
difference -0.38; 95% CI -74, -0.03; P = 0.03). However, 
no differences between groups were found in the mean 
frequency of binge eating episodes at the end of treatment 
(standardized mean difference -0.36; 95% CI -0.74–0.01; 
P = 0.06), in BMI (standardized mean difference 0.03; 95% 
CI -0.49–0.55), or in treatment discontinuation for any rea-
son (RR 1.35; 95% CI 0.61–3.00). The authors concluded 
that, in light of the frequent chronicity of BED, the data were 
not sufficient to recommend antidepressants formally as a 
single first-line therapy for short-term remission of binge 
eating episodes and weight reduction in BED patients.
Controlled combination therapy studies have had con-
trasting results. In one, diet counseling with psychological 
support plus imipramine was superior to diet counseling and 
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psychological support plus placebo for 8 weeks in decreasing 
binge eating (P , 0.01) and weight (P , 0.001).81 Benefits 
were maintained at 8-month follow-up despite discontinu-
ation of imipramine. In another 16-week trial, CBT with 
placebo and CBT with fluoxetine were both superior to flu-
oxetine alone and placebo alone for decreasing binge eating.77 
There was no difference between fluoxetine and placebo, 
though patients who responded early to fluoxetine continued 
to do well, while lack of early response was associated with 
failure to achieve remission.90 There was no additive effect 
for the combination of fluoxetine plus CBT over CBT alone 
for decreasing binge eating, and no single or combined 
treatment was effective for weight loss. In the third study, 
116 patients with BED receiving group behavioral weight 
control treatment for 20 weeks were randomized twice to 
adjunctive CBT or no CBT and to fluoxetine 40–80 mg 
daily or placebo.86 CBT, but not adjunctive fluoxetine, was 
effective for reducing binge eating. However, fluoxetine was 
effective for decreasing depressive symptoms. Neither CBT 
alone, fluoxetine alone, nor their combination were effective 
for weight loss.
Two randomized, placebo-controlled trials showed that 
SSRIs (fluvoxamine and fluoxetine) may be modestly effec-
tive in reducing relapse to binge eating in bulimia nervosa,91,92 
but comparable relapse prevention studies of antidepres-
sant monotherapy in BED have not yet been conducted. 
  Open-label data have suggested that some patients with BED 
who initially respond to SSRIs with decreased binge eating 
and weight loss may maintain these beneficial effects for up 
to 6 months with continuation of the SSRI.93,94 On the other 
hand, a 2-year follow-up study found that fluoxetine contin-
ued to be ineffective for binge eating or weight reduction after 
it was ineffective during an initial 5-month phase, though 
the drug remained effective for depressive symptoms.86,95 
Of note, 77% of patients in this study receiving medication 
were unblinded before or at the end of the initial 5-month 
phase of treatment.
Several promising antidepressants have not yet been 
  studied in BED in randomized, placebo-controlled trials. 
These include bupropion, the serotonin-norepinephrine 
reuptake inhibitors venlafaxine, desvenlafaxine, and 
milnacipran, and the novel dual activity antidepressant, 
  vilazodone, an SSRI and partial agonist at the serotonin 
5HT1A receptor. According to ClinicalTrials.gov, a random-
ized, placebo-controlled trial of bupropion in binge eating 
disorder and obesity is ongoing (NCT00414167; retrieved 
April 25, 2012). Also, a retrospective clinical analysis has sug-
gested that bupropion may be associated with greater weight 
loss than sertraline for BED patients.96 Another retrospective 
chart review found that venlafaxine was effective for reduc-
ing binge eating and body weight in 33 patients with BED 
and obesity.97   Vilazodone may be promising in light of its 
partial agonism at the serotonin 5HT1A receptor, and clarify 
the involvement of this receptor subtype in binge eating.98
Antiobesity agents
At least two rationales led to studies of antiobesity agents in 
BED. First is that BED is associated with obesity and anti-
obesity agents cause weight loss. Second is that antiobesity 
agents may have antibinge eating properties, either directly 
through appetite suppressant or satiety-enhancing proper-
ties or indirectly through metabolic effects. The antiobesity 
agents studied thus far for BED in randomized controlled 
trials have been sibutramine, orlistat, and d-fenfluramine 
(Table 3). Although sibutramine and d-fenfluramine have 
been removed from the worldwide market because of safety 
concerns, all three drugs will be reviewed for scientific 
completeness.
Fenfluramine
Fenfluramine and its isomer d-fenfluramine (the more selec-
tive dextro enantiomer of racemic d, l-fenfluramine) are 
efficacious weight loss drugs with strong proserotonergic 
properties. D-fenfluramine inhibits the reuptake of serotonin, 
while its metabolite d-norfenfluramine is a potent serotonin 
reuptake inhibitor and serotonin releaser.99 The role of sero-
tonin in enhancing satiety and the weight loss properties of 
d-fenfluramine led to one randomized controlled trial of the 
drug in BED before it was removed from the worldwide 
market in 1997 because of concerns that it caused cardiac 
valvular abnormalities and pulmonary hypertension.100,101 
In that study, 28 women with BED and obesity received 
d-fenfluramine up to 30 mg/day or placebo for 8 weeks.102 
In the 24 women who completed the trial, the rate of binge 
eating fell three times more rapidly in the d-fenfluramine 
group than in the placebo group. However, no significant 
weight changes were observed. Nonetheless, 4 months after 
discontinuation of d-fenfluramine, binge eating had increased 
to pretreatment levels.
Sibutramine
Sibutramine is a reuptake inhibitor of norepinephrine, sero-
tonin, and, to a lesser extent, dopamine, that is thought to 
cause weight loss by increasing satiety.103 It was removed 
from the worldwide market in 2010 because of an increased 
risk of myocardial infarction and stroke (but not death) 
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found in obese or overweight persons with pre-existing 
  cardiovascular disease.104
Three placebo-controlled studies, including one large 
multicenter trial, have been conducted with sibutramine 
(Table 3). In the first study, 60 patients with DSM-IV BED 
and obesity were randomly assigned to sibutramine 15 mg/day 
(n = 30) or placebo (n = 30) for 12 weeks at two centers.105 
Compared with placebo, sibutramine was associated with 
a significant reduction in number of binge days, greater 
weight loss, and significantly greater decreases in Binge 
Eating Scale and Beck Depression Inventory scores. Seven 
(23%) sibutramine patients and five (17%) placebo patients 
did not complete the trial. Dry mouth and constipation were 
more common with sibutramine than placebo. In the second 
study, 20 women with BED by DSM-IV criteria and obesity 
were randomized to receive sibutramine 10 mg/day (n = 10) 
or placebo (n = 10) for 12 weeks.106 At study end, average 
binge day frequency was significantly decreased among 
women receiving sibutramine (from 4.4 ± 1.0 to 1.0 ± 1.0; 
P , 0.001) but unchanged among those receiving placebo 
(from 4.7 ± 1.3 to 4.4 ± 0.5). Similarly, Body-Esteem Scale107 
scores improved significantly among sibutramine-treated 
patients but not among those given placebo. The average 
weight loss among sibutramine recipients (4.5 ± 2.1 kg) was 
significantly (P , 0.001) greater than that among placebo 
recipients (0.6 ± 05 kg). The most common adverse events 
with sibutramine were dry mouth and constipation.
The third study was a multisite trial in which 304 partici-
pants with DSM-IV BED were randomized to sibutramine 
(15 mg/day; n = 152) or placebo (n = 152) for 24 weeks at 18 
centers. All patients received dietary/life style psychoeduca-
tion. Compared with placebo-treated patients, sibutramine-
treated patients had significantly greater reductions in weekly 
binge frequency (sibutramine group mean 2.7%, placebo 
group mean 2.0%), binge day frequency, weight, BMI, and 
measures of cognitive restraint, disinhibition, and hunger as 
assessed by the Three Factor Eating Questionnaire (TFEQ). 
Sibutramine-treated patients also showed significantly greater 
global improvement and level of response, including remis-
sion of binge eating (59% for sibutramine versus 43% for 
placebo). More sibutramine recipients (67%) than placebo 
recipients (57%) completed the study. Headache, dry mouth, 
constipation, insomnia, and dizziness were significantly more 
common with sibutramine.
Orlistat
Orlistat is a gastrointestinal lipase inhibitor indicated for 
weight loss and weight maintenance.103 Its mechanism 
of action is inhibition of absorption of dietary fat. Two 
randomized, placebo-controlled studies have been conducted 
with orlistat in BED. In one study, 50 patients with BED by 
DSM-IV criteria and obesity were randomized to receive 
individual CBT delivered by guided self-help (CBTgsh) 
in combination with orlistat 120 mg three times daily or 
CBTgsh in combination with placebo for 12 weeks.87 At 
the 12-week time point, both CBTgsh and study medica-
tion were discontinued and the double-blind for medication 
was broken. Patients were again evaluated at 3-month 
follow-up. There were two primary outcomes, ie, remission 
of binge eating, defined as no binge eating episodes in the 
past month, and weight loss, defined as losing at least 5% 
of weight from baseline. Binge eating remission rates were 
significantly higher for orlistat plus CBTgsh than for placebo 
plush CBTgsh at post-treatment (64% versus 36%) but not at 
3-month follow-up (52% in both groups). However, rates for 
achieving at least 5% weight loss were significantly higher 
for the orlistat group at both post-treatment (36% versus 8%) 
and 3-month follow-up (32% versus 8%).
In the second study, 89 patients with BED by DSM-IV 
criteria and obesity were randomized to orlistat 120 mg 
three times daily (n = 44) or placebo (n = 45) for 24 weeks, 
both in combination with a mildly hypocaloric diet.108 Mean 
percentage weight loss (the primary outcome) was signifi-
cantly greater for orlistat-treated patients than for placebo-
treated patients (-7.4% versus -2.3%; P = 0.0001). Waist 
circumference, hip circumference, total percentage body 
fat, total cholesterol level, diastolic blood pressure, and 
insulin level were also significantly improved with orlistat. 
  Effectiveness of orlistat in binge eating per se was less clear. 
At 24 weeks, the mean number of binge eating episodes 
per week was numerically but not significantly decreased 
(1.0 for orlistat-treated patients versus 1.7 for placebo-treated 
patients). Also, similar rates of patients in both groups who 
completed the study continued to suffer from BED (23% for 
orlistat versus 29% for placebo). However, Eating Disorder 
Inventory scores at week 24 were significantly lower for 
orlistat than placebo (P = 0.011). In addition, fat intake was 
significantly lower in orlistat-treated patients at week 12; total 
caloric intake was significantly lower at week 24. Eighteen 
patients discontinued the study prematurely, five (11%) in the 
orlistat group and 13 (29%) in the placebo group. No patient 
discontinued orlistat because of an adverse event. Data on 
side effects were otherwise not reported.
These studies are noteworthy because they suggest that 
a drug with no direct action on the central nervous system 
(the bioavailability of orlistat is ,1%) may have beneficial 
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effects in BED.103 Of note, orlistat misuse has been reported 
in patients with eating disorders, including those with bulimia 
nervosa97,109 and BED.110
Other antiobesity agents
Phentermine is the most commonly prescribed medication 
for obesity in the US, and is approved for short-term use.63 
It is a sympathomimetic amine that is thought to suppress 
appetite by promoting norepinephrine release.111 Side effect 
concerns include elevation of pulse and blood pressure. 
Phentermine is currently under evaluation as a component 
in combination with topiramate and with pramlintide for 
weight loss in obesity.63,112,113
There are no reports of phentermine monotherapy 
in BED, but two open-label trials evaluated the drug in 
  combination with other treatments. In a six-month study, 
administration of phentermine 15 mg/day plus fenflu-
ramine 60 mg/day, to 22 severe binge eaters, 17 moderate 
binge eaters, and 16 nonbinge eaters, resulted in improved 
binge eating and Beck Depression Inventory scores in all 
three groups.114 In addition, 73% of the severe binge eaters, 
59% of the moderate binge eaters, and 69% of the nonbinge 
eaters experienced more than 10% weight loss. However, of 
35 patients who received echocardiograms, 20 had evidence 
of valvular insufficiency in one or more valves. In the second 
study, phentermine up to 30 mg/day, in combination with 
fluoxetine up to 60 mg/day, and CBT was assessed in 16 
obese women with binge eating, 14 of whom met DSM-IV 
criteria for BED.115 During the 20-week active treatment 
phase, mean weekly binge frequency declined by 95% 
from baseline, with 12 (75%) patients showing complete 
remission. Mean body weight and BMI declined by 8.6% 
and 8.7%, respectively, from baseline. After 6 months of 
subsequent maintenance treatment, 12 patients remained 
on study medication (10 patients on both agents and two 
patients on fluoxetine alone); binge frequency was 63% 
lower than at the start of treatment, but only five (42%) of 
the 12 patients were binge-free. Only six patients completed 
18 months of maintenance therapy; two were taking both 
medications and four were taking fluoxetine alone. Four of 
five BED patients were in remission from binge eating, but 
patients had regained most of the weight they had lost at the 
end of active treatment.
Antiepileptic drugs
Several rationales have prompted studies of antiepileptic 
drugs in BED. First is that early investigators noted that some 
patients with binge eating episodes and   electrocardiographic 
abnormalities stopped binge eating when treated with 
phenytoin.116–119 Second is that BED co-occurs with a number 
of conditions that respond to various antiepileptic agents, 
including mood, alcohol use, and borderline personality 
disorders.120 Third is that some antiepileptic drugs are associ-
ated with weight loss and/or anorexia,50 and have been shown 
to be efficacious as weight loss agents in obesity, either as 
monotherapy (eg, topiramate and zonisamide)121,122 or as 
components of combination therapies (eg, topiramate with 
phentermine, and zonisamide with bupropion).63,113 Fourth is 
that a number antiepileptic drugs affect neurotransmitter or 
peptide systems involved in regulation of feeding behavior. 
As noted earlier, topiramate affects the glutamate and neu-
ropeptide Y systems, while zonisamide affects neuropeptide 
Y and enhances serotonin and dopamine function.53,56,57 The 
antiepileptic drugs studied thus far in BED in randomized, 
controlled trials include topiramate, zonisamide, and lam-
otrigine. Phenytoin has been studied in the similar condition 
compulsive or binge eating.122
Topiramate
Topiramate is a sulfamate-substituted monosaccharide that 
is approved for epilepsy and migraine. It has multiple phar-
macological properties, including antagonism of the AMPA/
kainate glutamate receptor, state-dependent blockade of 
voltage-activated sodium channels, enhancement of gamma-
aminobutyric acid (GABA) activity at the GABA receptor, 
antagonism of high voltage-activated calcium channels, 
and inhibition of carbonic anhydrase.55,123,124 In randomized 
placebo-controlled trials in obese individuals without BED, 
topiramate monotherapy produces weight loss of about 
6–8 kg at 24 weeks with improvements in lipid parameters, 
glycemic control, and blood pressure.125–127 A large program 
sponsored by Vivus exploring the combination of low-dose 
controlled-release topiramate with phentermine (at both 
46/7.5 mg/day and 92/15 mg/day) in obesity has shown 
that this combination is efficacious and well tolerated for 
acute weight loss and long-term weight maintenance.128–130 
Moreover, this combination was associated with improved 
cardiovascular and metabolic variables and a decreased rate 
of incident diabetes.
Three randomized, placebo-controlled trials of topiramate 
have been published to date in BED. In the first study, 61 BED 
patients with obesity received topiramate (n = 30) or placebo 
(n = 31) for 14 weeks.83 Topiramate was started at 50 mg/day 
and could be increased to a maximum of 600 mg/day 
according to response and tolerability.   Topiramate (median 
dose 212 mg/day) was significantly superior to placebo in 
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reducing binge frequency, as well as obsessive-compulsive 
features of binge eating symptoms, as assessed with the 
Yale–Brown Obsessive Compulsive Scale Modified for 
Binge Eating (YBOCS-BE), global severity of illness, body 
weight, and BMI. Topiramate-treated patients experienced 
a 94% reduction in binge frequency and a mean weight loss 
of 5.9 kg, whereas placebo-treated patients experienced a 
46% reduction in binge frequency and a mean weight loss of 
1.2 kg. However, the dropout rate was high, with 14 (47%) 
topiramate recipients and 12 (39%) placebo recipients fail-
ing to complete the trial. Paresthesias, dry mouth, headache, 
and dyspepsia were the most common side effects associated 
with topiramate.
The second controlled study was a multicenter trial in 
which 407 patients with BED and at least three binge eating 
days/week, BMI 30–52 kg/m2, and no current psychiatric 
disorders or substance abuse were randomized to receive 
topiramate or placebo for 16 weeks.61 Topiramate was 
started at 25 mg/day and increased over an 8-week period 
to 400 mg/day or the maximum tolerated dose; the median 
final dose was 300 mg/day. Thirteen enrolled patients failed 
to meet the inclusion criteria, resulting in 195 topiramate 
and 199 placebo patients who were evaluated for efficacy. 
  Compared with placebo, topiramate significantly reduced 
weekly binge day frequency (-3.5 ± 1.9 versus -2.5 ± 2.1), 
binge frequency (-5.0 ± 4.3 versus -3.4 ± 3.8), weight 
(-4.5 ± 5.1 kg versus 0.2 ± 3.2 kg), and BMI (-1.6 ± 1.8 kg/m2 
versus 0.1 ± 1.2 kg/m2, all P , 0.001). Topiramate also 
significantly decreased obsession, compulsion, and total 
scores of the YBOCS-BE; overall, motor, and nonplanning 
impulsiveness scores of the Barratt Impulsiveness Scale, 
version 11;131 cognitive restraint, disinhibition, and hunger 
subscores of the TFEQ; and overall, social, and family 
life disability scores of the Sheehan Disability Scale. Sig-
nificantly more topiramate-treated subjects (58%) achieved 
remission compared with placebo-treated subjects (29%; 
P , 0.001). Discontinuation rates were 30% in each group; 
adverse events were the most common reason for topiramate 
discontinuation (16% versus 8% for placebo). Paresthesias, 
upper respiratory tract infection, somnolence, and nausea 
were the most frequent side effects of topiramate.
The third controlled study of topiramate in BED was 
another multicenter trial in which 73 patients with BED 
and obesity were randomized to 19 sessions of CBT in 
conjunction with topiramate (n = 37) or placebo (n = 36) 
for 21 weeks.132 The final mean dose of topiramate was 
206 ± 36 mg/day. Both treatment groups showed significant 
reductions in binge frequency. However, compared with 
patients receiving placebo, those receiving topiramate 
showed a significantly greater rate of weight reduction (the 
primary outcome measure) over the course of treatment 
(P , 0.001). Topiramate recipients also showed significantly 
greater mean weight loss (-6.8 kg) compared with placebo 
recipients (-0.9 kg). Reduction of binge frequencies and 
Binge Eating Scale and Beck Depression Inventory scores 
did not differ between the groups, but a greater proportion 
of topiramate-treated patients (84%) attained remission of 
binge eating as compared with placebo-treated patients (61%; 
P = 0.03). There was no difference between the groups with 
regard to completion rates. Paresthesias and taste perversion 
were more frequent with topiramate, whereas insomnia was 
more frequent with placebo. The authors concluded that 
adding topiramate to CBT improved the efficacy of the latter 
for BED, enhancing both weight loss and binge remission 
over the short term.132
There have been no randomized, placebo-controlled 
maintenance studies of antiepileptic drugs in BED. An open-
label extension trial suggested that the antibinge eating and 
weight loss effects of topiramate may be maintained over the 
long term. BED patients who completed the first randomized, 
placebo-controlled study of topiramate (n = 35) were offered 
participation in a 42-week open-label extension study of 
the drug.133 An analysis was conducted for 44 patients who 
received at least one dose of topiramate (31 who received 
topiramate in the open-label trial plus 13 who received topi-
ramate in the double-blind study only); 43 patients provided 
outcome measures at a final median dose of 250 mg/day. 
Mean weekly binge frequency declined significantly from 
baseline to the final visit for all 43 patients (-3.2; P , 0.001), 
for the 15 patients who received topiramate during the 
controlled and open-label studies (-4.0; P , 0.001), and 
for the 15 patients who received topiramate only during the 
open-label trial (-2.5; P = 0.044). Patients also exhibited a 
statistically significant reduction in body weight. However, 
only 10 (32%) of the 31 patients entering the extension trial 
completed the 42 weeks of open-label treatment, with the 
most common reasons for topiramate discontinuation being 
protocol nonadherence (n = 11) and adverse events (n = 8).
There are notable open-label descriptions of the beneficial 
use of topiramate in difficult-to-treat patients with BED. 
Thus, topiramate has been reported to reduce binge eating 
and/or overweight in BED patients with treatment-resistant 
illness, comorbid depressive or bipolar disorders, traumatic 
brain injury, and those receiving the drug adjunctively with 
antidepressants and/or mood stabilizers.134–138 Topiramate has 
also been used successfully to reduce binge eating and weight 
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loss difficulties after adjustable gastric banding or gastric 
bypass surgery.139,140 On the other hand, there are reports of 
topiramate misuse in eating disorder patients.141
Zonisamide
Zonisamide is a second-generation antiepileptic drug with 
broad-spectrum efficacy. It has many pharmacologic prop-
erties, including antagonism of voltage-gated sodium and 
T-type calcium channels, reduction of glutamate transmission 
by blockade of potassium-evoked glutamate release and 
upregulation of excitatory amino acid carrier-1, modula-
tion of central dopaminergic and serotonergic function, and 
carbonic anhydrase inhibition.53,142 A large program spon-
sored by Orexigen Therapeutics evaluating zonisamide in 
combination with bupropion in obesity has shown that the 
combination is associated with more weight loss than either 
drug alone.143,144
One randomized controlled study of zonisamide has been 
published in BED.142 In that study, 60 patients with DSM-IV 
BED and obesity received flexible-dose (100–600 mg/day) 
zonisamide monotherapy (n = 30) or placebo (n = 30) for 
16 weeks. The mean zonisamide daily dose at endpoint 
was 436 ± 159 mg/day. Compared with placebo, zonis-
amide was associated with a significantly greater rate of 
reduction in binge frequency (P = 0.021), body weight 
(P , 0.0001), BMI (P = 0.0001), and scores on the Clini-
cal Global Impression-Severity (P , 0.0001), YBOCS-BE 
(P , 0.0001), and TFEQ disinhibition (P , 0.0001) scales. 
Plasma ghrelin concentrations increased with zonisamide but 
decreased with placebo (P = 0.0001). However, the attrition 
rate was high, with 18 (60%) zonisamide-treated patients 
and 12 (40%) placebo-treated patients failing to complete 
the 12-week treatment period. Eight zonisamide recipients 
discontinued for adverse events. The most common reasons 
for stopping zonisamide were cognitive complaints (n = 2), 
psychological complaints (n = 2), and bone fracture (n = 2). 
The most common side effects associated with zonisamide 
were dry mouth, somnolence, headache, nausea, nervousness, 
and altered taste. This trial was consistent with an earlier 
open-label study in which zonisamide was associated with 
reduced binge eating and body weight but also with a high 
discontinuation rate.145
Lamotrigine
Lamotrigine is a broad-spectrum antiepileptic agent with 
regulatory approval for maintenance treatment of bipolar dis-
order in many countries. Pharmacodynamic actions include 
reduction of presynaptic glutamate release.55,123 The drug 
has been evaluated in one randomized, placebo-controlled 
trial in 51 patients with BED and obesity.146 Because lam-
otrigine and placebo had similarly high rates of reduction 
of weekly frequency of binge-eating episodes, the efficacy 
of lamotrigine in BED could not be determined. However, 
lamotrigine was associated with a numerically greater amount 
of weight loss (1.17 kg for lamotrigine versus 0.15 kg for 
placebo) and statistically significant reductions in fasting 
levels of glucose, insulin, and triglycerides, consistent with 
the finding that lamotrigine is associated with weight loss in 
healthy patients with obesity.147
Phenytoin
Two published placebo-controlled crossover studies of 
phenytoin in patients with compulsive or binge eating 
had contrasting results.117 In the negative trial, four obese 
patients with compulsive eating showed no significant dif-
ferences between phenytoin and placebo on any outcome 
measure.148 In addition, no patient had a marked response 
to phenytoin. In the positive study, 19 of 20 women with 
“binge eating   syndrome” completed 12 weeks during which 
they received phenytoin and placebo for six weeks each 
in a counterbalanced design.149 Twelve patients had final 
serum phenytoin levels of 10–20 µ/mL, and five had levels 
of 5–10 µ/mL. Patients given phenytoin first experienced a 
37% decrease in binge frequency (P , 0.01), but showed 
no change in binge frequency when switched to placebo. 
Patients given placebo first experienced no change in 
binge frequency, and did experience a 39% decrease after 
switching to phenytoin (P , 0.01). Eight (42%) patients 
displayed a moderate or better response ($50% reduction 
in binge episode frequency) on phenytoin, but only one 
patient experienced a remission of binge eating. When the 
two groups were compared, there were significantly fewer 
binges in the phenytoin-placebo group than in the placebo-
phenytoin group (P , 0.02),   indicating a carryover effect 
for the phenytoin-first sequence.
Other antiepileptics
A case series of nine obese patients with BED treated with 
oxcarbazepine had inconsistent findings.150 Four patients 
showed a decrease in binge eating and three lost weight. 
However, three patients reported no change in binge eating, 
two showed no weight change, and five gained weight. Five 
patients discontinued the drug and seven reported side effects. 
The authors noted that the drug appeared to be beneficial 
for patients with impulsive eating behaviors and depressive 
symptoms. In contrast, valproate has been reported to worsen 
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binge eating and enhance weight gain in patients with BED 
and comorbid bipolar disorder.138
Drugs for attention deficit  
hyperactivity disorder
Several rationales have prompted studies of attention deficit 
hyperactivity disorder medications in BED. First is that most 
drugs used to treat attention deficit hyperactivity disorder 
facilitate function of the dopamine and/or norepinephrine 
systems, which are involved in eating behavior and reward 
as well as in the biology of binge eating.37,74,151 Second, many 
drugs used to treat attention deficit hyperactivity disorder are 
associated with weight loss or anorectic effects, and there are 
preliminary reports that stimulants such as methylamphet-
amine and methylphenidate reduce binge eating in patients 
with bulimia nervosa.152–156 Third, epidemiological data have 
indicated a relationship between BED and attention deficit 
hyperactivity disorder in both adolescents28 and adults.3 
These observations have led to studies of atomoxetine, 
methylphenidate, and lisdexamfetamine in BED.
Norepinephrine reuptake inhibitors
Atomoxetine is a highly selective norepinephrine reuptake 
inhibitor approved by the US Food and Drug Administration 
for the treatment of attention deficit hyperactivity disorder. In 
the only controlled study of atomoxetine in BED, 40 patients 
were randomized to receive the active drug or placebo for 
10 weeks at a single center.61 Atomoxetine was flexibly 
dosed at 40–120 mg/day; the mean dose at endpoint evalua-
tion was 106 ± 21 mg/day. Compared with placebo-treated 
patients (n = 20), atomoxetine-treated patients (n = 20) 
showed a significantly greater decrease in binge frequency 
(the primary outcome measure), as well as in binge day 
frequency, weight, BMI, and scores on the Clinical Global 
Impression-Severity scale, YBOCS-BE obsession subscale, 
and TFEQ hunger subscale. Fifteen patients (six receiving 
atomoxetine) did not complete the 10-week trial. The most 
common side effects associated with atomoxetine were dry 
mouth, nausea, nervousness, insomnia, headache, constipa-
tion, and sweating. The only other selective norepinephrine 
reuptake inhibitor studied in BED has been reboxetine. In a 
12-week open-label trial in nine patients, significant reduc-
tions were seen in binge frequency and BMI.157
Stimulants
A double-blind, placebo-controlled crossover study in 
32 patients with BED and 46 healthy age-matched con-
trols showed that BED patients with at least one copy of 
the   nine-repeat allele of the dopamine transporter showed 
significant appetite suppression in response to methylpheni-
date compared with controls with this allele or BED patients 
with the 10/10 genotype, whose methylphenidate response 
was indistinguishable from placebo.158 The authors hypoth-
esized that a currently unknown genetic variant, which is over-
represented in BED, interacts with the dopamine transporter 
to suppress appetite in response to stimulant administration.
Lisdexamfetamine is a prodrug of d-amphetamine 
marketed for the treatment of attention deficit hyperactivity 
disorder in children and adults. Amphetamine inhibits 
the reuptake and enhances the release of dopamine and 
  norepinephrine.111 Two randomized, placebo-controlled trials 
of this compound are presently ongoing in patients with BED 
by DSM-IV criteria (NCT01090713 and NCT01291173; 
retrieved April 25, 2012).1
Antiaddiction drugs
The pharmacotherapy of addictive disorders has gained consider-
able empirical support, such that a class of “  anticraving” drugs 
has been hypothesized to exist that reduces cravings or urges 
to use alcohol or drugs of abuse.159 Growing research suggests 
addictive processes, including addiction to highly palatable 
food, are involved in the development and maintenance of 
obesity.160 Eating disorders with binge eating, including BED, 
also appear to be related to addictive disorders, though their 
precise relationships to food addiction per se have not been fully 
elucidated.161 Thus, the binge eating of BED is characterized by 
craving for food and loss of control over eating that are similar 
to the craving for alcohol and drugs and loss of control over the 
use of these substances that is seen in persons with addiction. 
Additionally, BED is associated with elevated rates of substance 
use disorders.3,28 These observations have led to the hypothesis 
that binge eating and addiction may share a common pathophysi-
ology involving highly palatable food and drugs of abuse com-
peting for the same brain reward circuitry, and that anticraving 
drugs may reduce the urge to binge by modulating neurotrans-
mission in the systems that comprise this circuitry.162
Opioid antagonists
Involvement of the endogenous opioid system in eating behav-
ior, reward, and addiction has prompted a number of studies of 
opioid antagonists in the treatment of binge-eating populations. 
Though placebo-controlled trials of naltrexone at standard 
doses in bulimia nervosa have largely been negative,75,163 
other studies in bulimia nervosa and open reports in BED 
have suggested that supratherapeutic doses (200–400 mg/day) 
may decrease binge eating.164–166 In a study of 41 women, 
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intravenous administration of the opioid antagonist, naloxone, 
selectively suppressed the consumption of sweet high-fat foods 
in obese and lean subjects with bulimia nervosa (n = 20), 
but not in controls (n = 21).167 Moreover, a large program 
sponsored by Orexigen Therapeutics evaluating naltrexone 
in combination with bupropion in obesity has shown that the 
combination is associated with more weight loss than either 
drug alone.168–170
In the only randomized controlled trial of naltrexone to 
include patients with BED, 33 obese bingers and 22 normal 
weight bulimics were treated for 8 weeks with naltrexone 
100–150 mg/day, imipramine, or placebo.75 Naltrexone did 
not significantly reduce binge duration or binge frequency 
in the obese bingers. However, three favorable case reports 
of naltrexone in BED have been published. One was a 
positive on-off-on case of naltrexone monotherapy using 
doses of 200 and 400 mg/day.171 The two others described 
the successful augmentation of fluoxetine using naltrexone 
100 mg/day.172,173 There are also reports of opioid antago-
nists being helpful in BED patients with serious comorbid 
neuropsychiatric and medical disorders.166
ALKS-33 is a novel compound in clinical development by 
Alkermes for alcohol dependence that binds nonselectively 
to µ, κ, and δ opioid receptors.174 Unlike naltrexone, it does 
not undergo extensive first-pass metabolism and exhibits high 
oral bioavailability. A randomized, double-blind, placebo-
controlled, 6-week study designed to assess the safety and 
efficacy of ALKS 33 10 mg/day in 68 patients with BED 
was recently completed. While ALKS 33 demonstrated a 
significant reduction from baseline in the efficacy endpoint 
of self-reported weekly binge eating episodes, the reduc-
tion was not significantly different from that observed with 
placebo.175
Acamprosate
Acamprosate is a glutamate receptor modulator approved 
in many countries for maintenance of abstinence in patients 
with alcohol dependence. The drug antagonizes the gluta-
mate N-methyl-D-aspartate receptor and may also decrease 
mGluR5 function.123,176 In addition to the overlap between 
BED and addictive disorders, preclinical and clinical findings 
suggesting that reduction of glutamate function may decrease 
feeding behavior, including binge eating, prompted one ran-
domized, placebo-controlled trial in BED.162 Forty patients 
with BED received acamprosate (n = 20) or placebo (n = 20) 
for 10 weeks. The mean endpoint daily dose of acamprosate 
was 2597 ± 605 mg/day. Acamprosate was not associated 
with a significantly greater decrease in binge frequency or any 
other outcome measure in the primary longitudinal analysis. 
However, in the secondary endpoint analysis, acamprosate 
was associated with statistically significant improvement 
in binge day frequency and in measures of obsessive-
compulsive symptoms of binge eating, food craving, and 
quality of life. BMI decreased slightly with acamprosate and 
increased with placebo; among completers, BMI decreased 
significantly more for acamprosate recipients than placebo 
recipients (P = 0.04). In addition, the drug was well tolerated, 
with a significantly higher completion (79%) rate than for 
placebo (45%, P = 0.05). Consistent with its adverse event 
profile in alcohol-dependent patients, diarrhea was the more 
common side effect. There were no serious adverse events.
Other agents
Memantine, a glutamate-modulating agent, has been reported 
to reduce binge eating in BED in two open-label trials. In 
the first trial, five women with BED and obesity received 
memantine 10 mg in the morning and 10–20 mg in the late 
afternoon. As a group, they also lost weight, on average, 
1.2 kg per week.177 In the second, 16 patients received a 
mean endpoint memantine dose of 18.3 mg/day. Although 
they did not lose weight as a group, weight loss was seen in 
four patients who had a remission of binge eating.178
Sodium oxybate, the sodium salt of gamma-  hydroxybutyrate, 
is a Schedule III drug marketed for the treatment of exces-
sive daytime sleepiness and cataplexy in patients with 
narcolepsy.179 Present in human brain as a metabolite of 
GABA, and with at least two identified receptors, gamma-
hydroxybutyrate modulates a number of neurotransmitters 
involved in the regulation of feeding behavior, including 
GABA, dopamine, serotonin, opioids, and glutamate.180 
Findings that chronic gamma-hydroxybutyrate and gamma-
hydroxybutyrate analogs decrease aspects of excess feeding 
behavior, the anticraving properties of the drug, and evidence 
of a link between narcolepsy and binge eating prompted an 
open-label 16-week study of the drug in 12 patients with 
BED.181,182 Ten patients completed at least one post-baseline 
evaluation, and five completed the study. The mean endpoint 
dose was 7.1 ± 2.0 g/day. Sodium oxybate was associated 
with significant reductions in binge day and binge episode 
frequencies, as well as measures of clinical severity, eating 
pathology, obsessive-compulsive symptoms, food cravings, 
BMI, and body weight. Nine participants had remission of 
binge eating and five lost $5% of their baseline weight; all 
five of the latter participants had remission of binge eating.
Baclofen, a GABA(B) agonist, given at 60 mg/day for 
10 weeks has also been reported to reduce binge eating 
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  frequency in BED; however, in this study, two of four women 
with BED gained weight at the trial endpoint despite report-
ing reduced binge eating.183
There are no published controlled studies of   antipsychotics 
in BED. Rather, second-generation antipsychotics have been 
reported to induce or exacerbate binge eating in patients 
with binge eating-related disorders, including bulimia 
nervosa.184,185 Moreover, second-generation antipsychotics 
have been reported to induce or exacerbate binge eating, 
including syndromal BED, in patients receiving the drugs 
for psychotic disorders.186
Conclusion
Research into the pharmacotherapeutic treatment of BED 
is in its early stages. No single medication has received 
approval from a regulatory body for use in BED. Many of 
the available pharmacotherapy studies in BED are plagued 
by limitations, such as small sample size, a high placebo 
response, high dropout rates, and unclear generalizability 
of findings to real world clinical situations.187 No placebo-
controlled maintenance trial in a group of patients whose 
binge eating was in remission has yet been published. There 
have been no placebo-controlled pharmacotherapy studies 
devoted to BED patients who have had partial or inadequate 
responses to pharmacotherapy, psychotherapy, or bariatric 
surgery. Also, there have been no pharmacotherapy studies 
in children, adolescents, or older adults with BED. Moreover, 
except for obesity and major depressive disorder, there has 
been no pharmacotherapy study of patients with BED and a 
specified psychiatric or medical comorbidity.
However,  many  individuals  with  BED  receive 
pharmacotherapy,11,188 and several conclusions regarding 
the pharmacotherapy of BED from extant research can 
nonetheless be made. Substantial evidence indicates that 
antidepressants are modestly efficacious for binge eating 
in BED over the short term.21,89 Antidepressants, including 
the serotonin-norepinephrine reuptake inhibitor, duloxetine, 
may also be useful for the depressive symptoms and/or 
syndromes that may accompany BED. However, they do 
not appear to have clinically significant benefits on body 
weight, and their long-term efficacy in BED is not known. 
Nor do they appear to enhance the antibinge eating effects 
of CBT significantly. However, it is unknown whether these 
findings would generalize to other available antidepressants 
with different pharmacodynamic profiles, such as bupropion 
or vilazodone.
Considerable double-blind, placebo-controlled data show 
that topiramate is effective for binge eating in BED with 
obesity. These data also show that topiramate is effective 
for weight loss in this patient population and decreases both 
obsessive-compulsive eating pathology as well as features of 
trait impulsivity.61 One controlled study showed topiramate 
may enhance the effectiveness of CBT in BED,132 while an 
open-label study found the antibinge eating and weight loss 
effects of topiramate in BED may persist for up to one year 
(though drug discontinuation rates were high, in part due to 
adverse events).133 A comparable amount of controlled data 
show that sibutramine is effective for reduction of binge 
eating and weight loss in BED with obesity,62 but this drug 
is no longer available because of safety concerns. Orlistat, 
when used in combination with CBT or dietary therapy, 
leads to enhanced weight loss and possibly reduced binge 
eating.77,108 Other compounds that are presently available and 
that show promise for BED are zonisamide, naltrexone 
(especially at doses higher than those used for substance use 
disorders), stimulants, and glutamate-modulating agents 
(eg,   memantine). These compounds merit more systematic 
evaluation in BED.
Further pharmacotherapy research into BED is greatly 
needed at many levels. Randomized, placebo-controlled 
maintenance trials would be useful for antidepressants, 
topiramate, and orlistat in BED. Randomized control trials 
in which a novel medication strategy (eg, topiramate mainte-
nance treatment of  BED) is combined with a specific psycho-
logical treatment would be useful. As has been done in other 
major mental disorders, trials are needed to explore strategies 
Table 5 Examples of novel pharmacotherapies under investigation 
for obesity
Agent Putative mechanism of action  
for weight loss
Monotherapies
  Lorcaserin Selective 5-HT2C receptor agonism
  Tesofensine Reuptake inhibition of NE, DA,  
and 5HT
  Pramlintide, davalintide Amylin agonism
  Exenatide, liraglutide Glucagon-like peptide-1 agonism
  velneperit Neuropeptide Y Y5 receptor 
antagonism
Combination Therapies
  Bupropion plus naltrexone Sustained increase in α-MSH release
  Bupropion plus zonisamide Enhancement of central NE, DA,  
and 5HT function
  Topiramate plus phentermine Glutamate antagonism and increased 
central NE release
  Pramlintide plus metreleptin Combined amylin and leptin agonism
  Pramlintide plus phentermine Amylin agonism and increased 
central NE release
Abbreviations: DA, dopamine; 5HT, serotonin; α-MSH, α-melanocyte stimulating 
hormone; NE, norepinephrine.
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where medications are optimized, switched, augmented, 
or combined in patients with treatment-resistant BED.189 
For example, studies of topiramate in combination with 
antidepressants would be important in patients with inad-
equately responsive or chronic forms of BED, including 
those with comorbid depressive disorders.190 In addition, 
studies are needed in BED patients who have clinically 
important comorbidities beyond obesity and depression, 
such as bipolar disorder, anxiety disorders, substance use 
disorders, diabetes, hypertension, dyslipidemia, and meta-
bolic syndrome.3,7 For example, in epidemiologic samples, 
it has been estimated that 12% of individuals with BED 
have bipolar disorder, 65% have an anxiety disorder, and 
23% have a substance use disorder;3 while over 5-year 
prospective follow-up, 10% will develop diabetes, 24% 
hypertension, and 30% dyslipidemia.7
Studies with new compounds are also greatly needed in 
BED. Available drugs that may hold promise for BED and 
merit evaluation in randomized controlled trials include the 
serotonin-norepinephrine reuptake inhibitors desvenlafaxine, 
venlafaxine, and milnacipran; bupropion; the combined 
SSRI-5HT1A agonist vilazodone; memantine and other gluta-
mate-modulating agents, such as riluzole;64,191 and long-acting 
stimulant preparations, such as OROS-  methylphenidate. 
Novel compounds that hold promise for BED include some 
of those in development for obesity (Table 5) and mood 
disorders. Examples of such compounds being developed 
for obesity include tesofensine, a serotonin-norepinephrine-
dopamine (triple) reuptake inhibitor; selective 5-HT2C recep-
tor agonists (eg, lorcaserin); melanin-concentrating hormone 
receptor 1 antagonists; combination therapies (eg, bupropion 
sustained-release with naltrexone sustained-release, bupro-
pion with zonisamide, and topiramate with phentermine); and 
agents that target hormones and peptides that control appetite 
or regulate metabolism.60,65,192–198 Examples of such agents 
being developed for depression include triple reuptake inhibi-
tors, serotonin-melatonin agents, and corticotropin-releasing 
hormone antagonists.64,191,199 Drugs with potential for efficacy 
in both depression and obesity (eg, triple reuptake inhibi-
tors), as well as combination therapies for obesity, might be 
especially promising candidates for BED. The former (eg, 
tesofensine and amitifadine) share mechanistic features with 
sibutramine, while the latter contain components (eg, topi-
ramate and zonisamide) already shown effective in BED as 
monotherapy. Some of the many drugs in development for 
epilepsy might also be considered as potential therapeutic 
agents for BED, particularly if they are associated with ano-
rectic or weight loss properties.67
Rational comprehensive guidelines for the use of 
pharmacotherapy in BED need to be developed. These 
guidelines will need to address the role of pharmacotherapy 
relative to other treatment modalities for BED, including 
psychological strategies and bariatric surgery, as well as the 
individual roles of different medications. Some authorities 
suggest psychotherapy should be the first-line treatment of 
BED and that current pharmacotherapies cannot be recom-
mended because of insufficient evidence.10 However, this 
recommendation needs to account for patient preference, 
the incomplete effectiveness of psychotherapy, for the fact 
that pharmacotherapy can be combined with or added to all 
other BED treatments (both psychological and surgical), 
and for the potential lack of generalizability of the findings 
of psychotherapy studies. Moreover, BED is most likely to 
be a heterogeneous condition, and some patients may only 
respond optimally to pharmacotherapy, while others may 
respond to psychotherapy alone.200 Identification of factors 
predicting requirement of pharmacotherapy, along with the 
particular medications most likely to be effective, will help 
realize personalization of BED treatment.
Pharmacotherapy research for BED will need to be 
informed by advances in both clinical trial design, psycho-
biology, and molecular genetics. Regarding the former, there 
is presently a lack of consensus about what constitutes ideal 
clinical trial design in eating disorder pharmacotherapy 
research in general, and for BED in particular. This includes 
lack of agreement on assessment instruments, definitions of 
primary outcome and of response, remission, recovery, and 
relapse, stages of illness to be studied, metrics for reporting 
outcome, and how best to manage low completion rates.42,88 
Regarding the latter, intensive research is needed to identify 
endophenotypes, genes, and other psychological or biological 
markers that will predict response to treatment and facilitate 
novel drug discovery.20,201
In summary, pharmacotherapy has an important role 
in the management of BED, especially in patients inad-
equately responsive to psychotherapy and surgery, patients 
with comorbid psychiatric or medical disorders, and those 
with chronic or intractable illness. However, the available 
pharmacotherapeutic armamentarium for BED and its sup-
porting evidence base is far from adequate. Further study is 
needed to clarify which specific agents might be most use-
ful for which patient subgroups, as well as to delineate the 
larger role of pharmacotherapy in relationship to other BED 
treatments. Novel medical treatments for BED are needed. In 
particular, rational drug discovery devoted to BED needs to 
occur. In the meantime, current and future medications with 
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psychotropic benefits and/or favorable effects on appetite 
and weight might be considered as potential therapeutic 
agents for BED.
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